View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Mar. 20, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	EYENOVIA, INC.
Entity Central Index Key	0001682639
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 35,204,910
Trading Symbol	EYEN
Entity Common Stock, Shares Outstanding		12,019,148
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash	$ 19,728,200	$ 5,249,511
Prepaid expenses and other current assets	132,756	37,149
Total Current Assets	19,860,956	5,286,660
Property and equipment, net	36,738	27,960
Deferred offering costs	0	328,700
Security deposit	117,800	0
Total Assets	20,015,494	5,643,320
Current Liabilities:
Accounts payable	1,509,524	246,384
Accrued compensation	912,104	0
Accrued expenses and other current liabilities	677,213	306,263
Total Current Liabilities	3,098,841	552,647
Deferred rent	41,584	0
Total Liabilities	3,140,425	552,647
Commitments and contingencies (Note 7)
Stockholders' Equity:
Common stock, $0.0001 par value, 90,000,000 shares authorized; 11,468,996 and 2,566,530 shares issued and outstanding as of December 31, 2018 and 2017, respectively	1,147	257
Additional paid-in capital	53,388,216	24,351,138
Accumulated deficit	(36,514,294)	(19,261,186)
Total Stockholders' Equity	16,875,069	5,090,673
Total Liabilities and Stockholders' Equity	20,015,494	5,643,320
Series A Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	0	293
Total Stockholders' Equity	0	293
Series A-2 Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	0	79
Total Stockholders' Equity	0	79
Series B Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	0	92
Total Stockholders' Equity	$ 0	$ 92

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	6,000,000	6,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	11,468,996	2,566,530
Common Stock, Shares, Outstanding	11,468,996	2,566,530
Series A Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	20,000,000
Preferred Stock, Shares Issued	0	2,932,431
Preferred Stock, Shares Outstanding	0	2,932,431
Series A-2 Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	5,714,286
Preferred Stock, Shares Issued	0	788,827
Preferred Stock, Shares Outstanding	0	788,827
Series B Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	10,000,000
Preferred Stock, Shares Issued	0	918,983
Preferred Stock, Shares Outstanding	0	918,983

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Operating Expenses:
Research and development	$ 11,119,096	$ 3,816,732
General and administrative	6,137,347	1,315,635
Total Operating Expenses	17,256,443	5,132,367
Loss From Operations	(17,256,443)	(5,132,367)
Other Income:
Interest income	3,335	2,380
Net Loss	$ (17,253,108)	$ (5,129,987)
Net Loss Per Share
- Basic and Diluted	$ (1.82)	$ (2.19)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	9,476,706	2,344,712

Statements of Changes in Stockholders' Equity - USD ($)

Total

Common Stock [Member]

Additional Paid-In Capital [Member]

Accumulated Deficit [Member]

Series A Convertible Preferred Stock [Member]

Series A2 Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Balance at Dec. 31, 2016

$ 3,009,081

$ 227

$ 17,139,651

$ (14,131,199)

$ 323

$ 79.00

$ 0

Balance (in shares) at Dec. 31, 2016

2,266,667

3,232,294

788,827

Issuance of warrant

431,574

$ 0

431,574

$ 0

Issuance of Series B convertible preferred stock, net of issuance costs

^[1]

6,367,693

$ 0

6,367,601

$ 0

$ 92

Issuance of Series B convertible preferred stock, net of issuance costs (in shares)

^[1]

918,983

Conversion of Series A convertible preferred stock into common stock

$ 30

$ (30)

$ 0

Conversion of Series A convertible preferred stock into common stock (in shares)

299,863

(299,863)

Stock-based compensation

412,312

$ 0

412,312

$ 0

Net loss

(5,129,987)

Balance at Dec. 31, 2017

5,090,673

$ 257

24,351,138

(19,261,186)

$ 293

$ 79

$ 92

Balance (in shares) at Dec. 31, 2017

2,566,530

2,932,431

788,827

918,983

Conversion of convertible preferred stock into common stock upon completion of initial public offering

$ 470

(6)

$ (293)

$ (79)

$ (92)

Conversion of convertible preferred stock into common stock upon completion of initial public offering (in shares)

4,702,116

(2,932,431)

(788,827)

(918,983)

Issuance of common stock in initial public offering

^[1],[2]

24,547,803

$ 273

24,547,530

$ 0

Issuance of common stock in initial public offering (in shares)

^[1],[2]

2,730,000

Issuance of common stock in follow-on public offering

^[3]

2,817,749

$ 138

2,817,611

$ 0

Issuance of common stock in follow-on public offering (in shares)

^[3]

1,380,000

Exercise of warrants on a cashless basis

$ 6

(6)

$ 0

Exercise of warrants on a cashless basis (in shares)

61,385

Exercise of stock options

56,482

$ 3

56,479

$ 0

Exercise of stock options (in shares)

28,965

Stock-based compensation

1,615,470

$ 0

1,615,470

$ 0

Net loss

(17,253,108)

Balance at Dec. 31, 2018

$ 16,875,069

$ 1,147

$ 53,388,216

$ (36,514,294)

$ 0

Balance (in shares) at Dec. 31, 2018

11,468,996

[1]	Includes gross proceeds of $6,409,651, less issuance costs of $41,958.
[2]	Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.
[3]	Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.

Statements of Changes in Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2018 USD ($)
Series B Convertible Preferred Stock [Member]
Proceeds Of Stock Issued During Period Gross	$ 6,409,651
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	41,958
Common Stock One [Member]
Proceeds Of Stock Issued During Period Gross	27,300,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	2,752,197
Common Stock Two [Member]
Proceeds Of Stock Issued During Period Gross	3,381,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 563,251

Statements of Cash Flows - USD ($)

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Cash Flows From Operating Activities

Net loss

$ (17,253,108)

$ (5,129,987)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

19,129

25,466

Stock-based compensation

1,615,470

412,312

Changes in operating assets and liabilities:

Prepaid expenses and other current assets

(95,607)

(34,814)

Accounts payable

1,263,140

(55,647)

Accrued compensation

912,104

Accrued expenses and other current liabilities

503,950

51,560

Security deposit

(117,800)

Deferred rent

41,584

Net Cash Used In Operating Activities

(13,111,138)

(4,731,110)

Cash Flows From Investing Activities

Purchases of property and equipment

(27,907)

(10,234)

Net Cash Used In Investing Activities

(27,907)

(10,234)

Cash Flows From Financing Activities

Proceeds from sale of common stock in initial public offering

^[1]

25,089,000

Payment of initial public offering issuance costs

(345,497)

(195,700)

Proceeds from sale of common stock in follow-on public offering

^[2]

3,084,330

Payment of follow-on public offering issuance costs

(266,581)

Proceeds from exercise of stock options

56,482

Proceeds from sale of warrant

431,574

Proceeds from advances related to Series B Convertible Preferred Stock

6,409,651

Payment of Series B Convertible Preferred Stock issuance costs

(41,958)

Net Cash Provided By Financing Activities

27,617,734

6,603,567

Net Increase in Cash

14,478,689

1,862,223

Cash - Beginning of Period

5,249,511

3,387,288

Cash - End of Period

19,728,200

5,249,511

Supplemental Disclosure of Non-Cash Financing Activities

Conversion of convertible preferred stock into common stock

470

Exercise of warrants on a cashless basis

Accrual of deferred offering costs

133,000

Reversal of previously accrued initial public offering issuance costs

(133,000)

Reclassification to additional paid-in capital for initial public offering issuance costs that were previously paid

$ (195,700)

$ 0

[1]	Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.
[2]	Includes gross proceeds of $3,381,000, less issuance costs of $296,670 deducted directly from the offering proceeds.

Statements of Cash Flows (Parenthetical)	12 Months Ended
Statements of Cash Flows (Parenthetical)	Dec. 31, 2018 USD ($)
Common Stock One [Member]
Proceeds Of Stock Issued During Period Gross	$ 27,300,000
Payments of Debt Issuance Costs	2,211,000
Common Stock Two [Member]
Proceeds Of Stock Issued During Period Gross	3,381,000
Payments of Debt Issuance Costs	$ 296,670

Business Organization and Nature of Operations

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Business Organization and Nature of Operations

Eyenovia, Inc. (“Eyenovia” or the “Company”) was organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name, PGP Holdings V, Inc. On May 5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October 6, 2014, Eyenovia, Inc. reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.

Eyenovia is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet

. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that generally exceeded the efficacy of traditional eyedrop administration. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are not classified by the FDA as medical devices or drug-device combination products.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Liquidity and Financial Condition

The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

On January 29, 2018, the Company raised aggregate net proceeds of approximately $24.5 million in its initial public offering (“IPO”).

On December 21, 2018, the Company raised aggregate net proceeds of approximately $2.8 million in its follow-on public offering.

See Note 9 – Stockholders’ Equity – Public Offerings for additional details.

The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next twelve months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

Use of Estimates

Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

See Note 2 - Summary of Significant Accounting Policies — Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2018 and 2017, the Company had no cash equivalents.

The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December 31, 2018 and 2017, the Company had cash balances in excess of FDIC insurance limits of $19,478,200 and $4,999,511, respectively.

Property and Equipment, Net

Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.

Impairment of Long-lived Assets

The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2018 and 2017.

Deferred Offering Costs

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company’s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs are offset against the offering proceeds.

Preferred Stock

The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.

Convertible Instruments

The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 “Derivatives and Hedging” of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.

If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company’s common stock as of the commitment date to the effective conversion price of the instrument.

Fair Value of Financial Instruments

The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2018 and 2017. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

The Company’s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of

operations. The Company did not recognize any such penalties or interest during 2017 and 2018.

Research and Development

Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.

Stock-Based Compensation

During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management’s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide,

Valuation of Privately-Held-Company Equity Securities Issued as Compensation

. The estimates used by management are considered highly complex and subjective. During the year ended December 31, 2018, the Company used the prices quoted on the Nasdaq Capital Market to determine the fair value of its common stock.

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2018		2017
Options		2,220,868		1,684,416
Restricted Stock Units		20,165		-
Series A Convertible Preferred Stock		-		2,932,431
Series A-2 Convertible Preferred Stock		-		788,827
Series B Convertible Preferred Stock		-		918,983
Warrant		-		61,875
Total potentially dilutive shares		2,241,033		6,386,532

Subsequent Events

The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. The

Company does not expect the adoption of ASU 2016-15 will have a material impact on its financial position, results of operations, and cash flows.

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of operations, and cash flows.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, “Equity — Equity-Based Payments to Nonemployees.” The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASU No. 2014-09, (Topic 606), “Revenue from Contracts with Customers.” The Company is currently evaluating ASU 2018-07 and its impact on its financial position, results of operations and cash flows.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.

Recently Adopted Accounting Pronouncements

In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending after December 15, 2017 for share-based payment awards modified on or after the adoption date. The Company adopted this standard on January 1, 2018 and its adoption did not have a material impact on the Company’s financial position, results of operations or cash flows.

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2018

Prepaid Expense and Other Assets [Abstract]

Prepaid Expenses and Other Current Assets Disclosure [Text Block]

Note 3 – Prepaid Expenses and Other Current Assets

As of December 31, 2018 and 2017, prepaid expenses and other current assets consisted of the following:

	December 31,
	2018		2017
Prepaid rent and security deposit	$	75,729	$	-
Prepaid insurance expenses		39,465		384
Prepaid patent expenses		10,562		7,833
Prepaid conference expenses		7,000		-
Prepaid research and development expenses		-		28,932
Total prepaid expenses and other current assets	$	132,756	$	37,149

Property and Equipment, Net

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Note 4 – Property and Equipment, Net

As of December 31, 2018 and 2017, property and equipment consisted of the following:

	December 31,
	2018			2017
Equipment	$	62,886		$	34,979
Leasehold improvements		40,000			40,000
		102,886			74,979
Less: accumulated depreciation and amortization		(66,148	)		(47,019	)
Property and equipment, net	$	36,738		$	27,960

Depreciation and amortization expense was $19,129 and $25,466 for the years ended December 31, 2018 and 2017, respectively, of which $17,966 and $25,466 was included within research and development expenses and $1,163 and $0 was included in general and administrative expenses in the statements of operations for the years ended December 31, 2018 and 2017, respectively.

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

Note 5 – Accrued Expenses and Other Current Liabilities

As of December 31, 2018 and 2017, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2018		2017
Accrued research and development expenses		375,204		120,455
Accrued legal expenses		168,650		-
Accrued professional services		111,728		41,831
Other		12,165		1,134
Credit card payable		9,466		9,843
Accrued offering costs		-		133,000
Total accrued expenses and other current liabilities	$	677,213	$	306,263

Accrued Compensation

12 Months Ended

Dec. 31, 2018

Note 6 – Accrued Compensation

As of December 31, 2018 and 2017, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2018		2017
Accrued bonus expenses	$	694,490	$	-
Accrued payroll expenses		217,614		-
Total accrued expenses and other current liabilities	$	912,104	$	-

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note

7 – Income Taxes

The income tax (provision) benefit consists of the following:

	For The Year Ended
	December 31,
	2018			2017
Federal:
Current	$	-		$	-
Deferred		3,516,722			235,473
State and local:
Current		-			-
Deferred		47,238			80,301
		3,563,960			315,774
Change in valuation allowance		(3,563,960	)		(315,774	)
Income tax (provision) benefit	$	-		$	-

A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	For The Years Ended
	December 31,
	2018			2017
Tax benefit at federal statutory rate		21.0	%		34.0	%
State income taxes, net of federal benefit		0.3	%		4.0	%
Permanent differences		(0.8	)%		0.0	%
Research and development credits		2.8	%		6.3	%
Prior period adjustments and other		(2.6	)%		(8.1	)%
Effect of tax rate changes		0.0	%		(30.0	)%
Change in valuation allowance		(20.7	)%		(6.2	)%
Effective income tax rate		0.0	%		0.0	%

The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:

	December 31,
	2018			2017
Deferred Tax Assets:
Net operating loss carryforwards	$	5,453,854		$	2,588,641
Stock-based compensation		616,207			347,977
Research & development tax credits		1,008,443			526,134
Property & equipment		2,486			-
Intangible assets		310,230			364,508
Gross deferred tax assets		7,391,220			3,827,260
Valuation allowance		(7,391,220	)		(3,827,260	)
Deferred tax asset, net of valuation allowance	$	-		$	-

Changes in valuation allowance	$	(3,563,960	)	$	(315,774	)

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.

At December 31, 2018, we had federal net operating

loss carryforwards of approximately $25.6 million, of which, $14.8 million will never expire and $10.8 million will expire at various dates from 2034 to 2038. At December

31, 2018, the Company estimates that it has approximately $500,000 of New York State net operating losses that may be available to offset future taxable income.

In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforwards could become subject to annual limitations if there are greater than 50% ownership changes.

The Company files income tax returns in the U.S. federal jurisdiction, the State of New York and the State of Florida (where the Company filed its final return in 2015), which remain subject to examination by the various taxing authorities beginning with the tax year ended December 31, 2015.

The Tax Cuts and Jobs Act (the "Act") was enacted in December 2017. Among other things, the primary provision of Tax Reform impacting the Company is the reduction to the U.S. corporate income tax rate from 35% to 21%. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate in the period of enactment resulting in an income tax expense of approximately $1.5 million which is fully offset by the corresponding tax benefit of $1.5 million from the reduction in the valuation allowance in the year ended December 31, 2017. There were no specific impacts of Tax Reform that could not be reasonably estimated which the Company accounted for under the prior tax law.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 8 – Commitments and Contingencies

Operating Leases

On August 8, 2018, the Company entered into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The monthly base rent ranges from $19,633 to $22,486 per month over the term of the lease for a total base rent lease commitment of approximately $1,236,000. The lease expires on September 30, 2023. The security deposit is approximately $118,000.

Future minimum payments under this operating lease agreement are as follows as:

For the Year Ending December 31,	Minimum Lease Payments
2019	$	238,300
2020		244,853
2021		251,586
2022		258,505
2023		198,157
	$	1,191,401

See Note 8 – Related Party Transactions – Lease Agreements for details of a lease agreement with a related party.

Litigations, Claims and Assessments

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

The Company, its Chief Executive Officer and members of its Board of Directors were named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September 2, 2014 in connection with the Company’s Asset Purchase Agreement with Corinthian Ophthalmic, Inc. (“Corinthian”). A shareholder of Corinthian alleged a fraudulent transfer and sought to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018. On October 29, 2018, the parties entered into a Settlement Agreement pursuant to which the defendants agreed to pay the Corinthian shareholder $600,000 in exchange for the release of all related claims. While the Company is indemnified by Corinthian and Corinthian's applicable insurance policy provides coverage of $10 million, in an effort to avoid the additional legal costs and other resources required with a trial, the Company contributed $150,000 of the settlement amount (the remaining $450,000 was paid by Corinthian's insurance carrier), which was paid on October 29, 2018.

Related Party Transactions

12 Months Ended

Dec. 31, 2018

Note 9 – Related-Party Transactions

Consulting Agreements

The Company’s Chief Executive Officer and another member of its Board of Directors are partners in Private Medical Equity, Inc. (“PME”). The Company and PME were parties to a consulting agreement dated November 4, 2014 that provided for the payment of $33,200 per month to PME in consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is billed separately. During the year ended December 31, 2017, the Company incurred approximately $329,400 related to the agreement, of which, $176,344 was included within research and development expenses and $152,656 was included within general and administrative expenses on the statements of operations. On August 1, 2017, the agreement was terminated and the Company’s Chief Executive Officer became employed full time by the Company. The Board member now invoices the Company through a separate consulting agreement dated July 6, 2017 that is discussed below.

A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $162,929 and $85,835 for the years ended December 31, 2018 and 2017, respectively, related to the agreement which was included within general and administrative expenses on the statements of operations.

Lease Agreements

The Company paid $3,000 and $4,000 per month as of July 2016 and January 2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for its Chief Executive Officer. The Company left the space on August 31, 2018. The Company’s rent expense for this space amounted to $32,000 and $36,000 for the years ended December 31, 2018 and 2017, respectively, related to the office space, which was included within general and administrative expenses on the statements of operations.

The Company’s Vice President of Research and Development and Manufacturing (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The Company made $40,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense for this space amounted to $47,270 and $45,678 for the years ended December 31, 2018 and 2017, respectively.

Research and Development Activities

On July 6, 2017, the Company entered into an engagement letter with its VP of R&D. Pursuant to the terms of the engagement letter, starting on August 1, 2017, the VP of R&D was to provide service to the Company as a non-employee on a part-time basis in exchange for $9,167 per month and $175 per hour for any additional work. On July 7, 2017, the VP of R&D was granted options to purchase 100,264 shares of common stock at an exercise price of $1.95 per share, the fair value as of that date, that vest in equal monthly installments over 36 months starting from the date of grant. The options had a grant date fair value of $173,900. On August 16, 2017, the VP of R&D changed from a non-employee to an employee of the Company, but remained employed on a part-time basis at the same compensation rate. During 2018, the VP of R&D’s salary was increased to $165,000 per year in connection with the increase from two (2) to three (3) days of work per week. The Company recognized $182,275 and $27,500 of compensation expense related to the VP of R&D’s salary during the years ended December 31, 2018 and 2017, respectively.

The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2018 and 2017, the Company recognized research and development expense of $863,555 and $1,155,000, respectively, related to services provided by such vendor. As of December 31, 2018 and 2017, the Company had a liability of $100,667 and $94,998, respectively, to the vendor and a liability of $0 and $9,906, respectively, related to expenses incurred by the VP of R&D.

During 2015, the Company entered into a license agreement with Senju Pharmaceuticals Co., Ltd. (“Senju”) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a micro-dose product candidate in Asia, so no royalties had been earned. Senju is owned by the family of a member of the Company’s Board of Directors and both beneficially own greater than 5% of the Company’s common stock.

Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 10 – Stockholders’ Equity

Reverse Stock Split

Effective January 8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company’s issued and outstanding common stock and preferred stock (the “Reverse Split”). The number of authorized shares remained unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.

Authorized Capital

The Company is authorized to issue 90,000,000 shares of common stock, par value of $0.0001 per share, and 6,000,000 shares of preferred stock, par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share. The Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.

Equity Incentive Plans

On January 5, 2018, the Company’s Board of Directors and stockholders approved an amendment to the Company’s 2014 Equity Incentive Plan (“2014 Plan”) to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares. As of December 31, 2018, there were 12,833 shares available for future issuance under the 2014 Plan.

On March 6, 2018, the Company’s Board of Directors adopted the 2018 Omnibus Stock Incentive Plan (“2018 Plan”), subject to stockholder approval. The 2018 Plan provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units (“RSUs”) to employees, directors and consultants of the Company and its affiliates. The 2018 Plan was approved by Company stockholders at its annual meeting of stockholders on June 11, 2018. The 2018 Plan terminates on June 11, 2028. The 2018 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company’s common stock on the date of grant. There are 750,000 shares of common stock authorized under the 2018 Plan. As of December 31, 2018, there were 333,836 shares available for future issuance under the 2018 Plan.

Public Offerings

On January 29, 2018, the Company consummated its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, which were recorded as a reduction of additional paid-in capital.

On December 21, 2018, the Company consummated a follow-on public offering of 1,380,000 shares of its common stock at an offering price of $2.45 per share, generating $3.4 million and $2.8 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $0.6 million, which were recorded as a reduction of additional paid-in capital.

Series A and Series A-2 Convertible Preferred Stock

On July 6, 2017, the Company’s Board of Directors adopted, and the Company’s stockholders approved, the Second Amendment to the Company’s Certificate of Incorporation (the “Second Amendment”). Pursuant to the Second Amendment, in the event that any holder of shares of Series A Convertible Preferred Stock or Series A-2 Convertible Preferred Stock (collectively, the “Series A/A-2 Preferred Stock”) did not participate in a subsequent private financing (as defined in the Second Amendment) by purchasing in the aggregate, in such subsequent financing, at least 75% of such holder’s pro rata amount, then each share of Series A/A-2 Preferred Stock held by such holder would automatically be converted into common stock concurrently with the consummation of such subsequent financing. Such conversion is referred to as a “Special Mandatory Conversion.”

On September 27, 2017, in connection with the sale of Series B Convertible Preferred Stock, holders of an aggregate of 299,863 shares of Series A Convertible Preferred Stock did not participate in such financing by purchasing at least 75% of such holder’s pro rata amount. As a result, the Special Mandatory Conversion of the Series A/A-2 Preferred Stock was triggered and, accordingly, such shares of Series A Convertible Preferred stock were automatically converted into an aggregate of 299,863 shares of common stock.

The preferred stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and, therefore, it has been classified within stockholders’ equity on the balance sheet. While the embedded conversion option (“ECO”) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature because the conversion price exceeded the estimated fair value of the Company’s common stock as of the commitment date.

The Series A and Series A-2 Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters’ discounts and expenses, was at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering were not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series A and Series A-2 Convertible Preferred Stock converted immediately prior to the Company’s IPO. See Note 9 – Stockholders’ Equity – Conversion of Preferred Stock for additional details.

Series B Convertible Preferred Stock

During the year ended December 31, 2017, the Company sold an aggregate of 918,983 shares of its Series B Convertible Preferred Stock to investors at a price of $6.98 per share for aggregate gross proceeds of $6,409,651. The Company incurred $41,958 of legal costs in connection with the sale, such that the aggregate net proceeds from the sale were $6,367,693.

On November 9, 2017, the Board adopted resolutions ratifying each of the issuances of Series B Convertible Preferred Stock, which were then approved by the Company’s shareholders. On November 13, 2017, the Company filed a certificate of validation with the Delaware Secretary of State in respect of such ratifications, such that, as of that date, the Series B Convertible Preferred Stock was duly authorized, validly issued, fully paid and nonassessable.

The Series B Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock was automatically convertible into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series B Convertible Preferred Stock converted immediately prior to the Company’s IPO. See Note 9 – Stockholders’ Equity – Conversion of Preferred Stock for additional details.

The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders’ equity on the balance sheet. While the embedded conversion option (“ECO”) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company’s common stock as of the commitment date.

Conversion of Preferred Stock

Immediately prior to the closing of the IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,702,116 shares of the Company’s common stock.

Stock-Based Compensation

The Company records stock-based compensation expense related to stock options and RSUs. For the years ended December 31, 2018 and 2017, the Company recorded expense of $1,615,470 and $412,312, respectively. As of December 31, 2018, there was $3,730,911 of unrecognized stock-based compensation expense (of which $396,924 related to non-employee grants, which are subject to fair value adjustments), which the Company expects to recognize over a weighted average period of 2.2 years.

Restricted Stock Units

On July 24, 2018, the Company granted an aggregate of 20,165 RSUs to its directors under the 2018 Plan. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2019 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which will be recognized over the vesting period.

Stock Options

On July 7, 2017, the Company granted ten-year stock options to purchase an aggregate of 897,747 shares of common stock to its employees and consultants under the 2014 Plan. Of the 897,747 shares, (i) 100,002 vest monthly over 12 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, (ii) 797,745 shares vest monthly over 36 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company. The stock options have an exercise price of $1.95 per

share. The stock options

had an aggregate grant date fair value of $1,585,700, which the Company expects to recognize over the vesting period.

On April 16, 2018, the Compensation Committee of the Board of Directors approved the grant of ten-year stock options to purchase 175,668 shares of common stock to Company employees and consultants under the 2014 Plan. The stock options will vest in equal monthly increments over 36 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and have an exercise price of $8.72 per share, which was the closing stock price on the date of grant. The stock options had a grant date fair value of $1,412,700, which the Company expects to recognize over the vesting period.

During the year ended December 31, 2018, the Company granted ten-year stock options to purchase an aggregate of 395,999 shares of common stock to its employees, consultants and directors under the 2018 Plan. Of the 395,999 shares, (i) 313,674 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company, (ii) 60,000 vest monthly over 36 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and (iii) 22,325 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2019 annual stockholders meeting, subject to continued service to the Company. The stock options have exercise prices ranging from $5.10 per share to $6.30 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date value of $2,237,800, which the Company expects to recognize over the vesting period.

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Year Ended
	December 31,
	2018			2017
Expected term (years)		5.50 - 10.00			5.32 - 10.00
Risk free interest rate		2.69 - 3.24	%		1.95 - 2.39	%
Expected volatility		140 -141	%		130	%
Expected dividends		0.00	%		0.00	%

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

The weighted average estimated grant date fair value of the stock options granted for the years ended December 31, 2018 and 2017 was approximately $6.39 and $1.77 per share, respectively.

A summary of the option activity during the year ended December 31, 2018 is presented below:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value
Outstanding January 1, 2018		1,684,416		$	1.68
Granted		571,667			6.94
Exercised		(28,965	)		1.95
Forfeited		(6,250	)		8.72
Outstanding December 31, 2018		2,220,868		$	3.01		8.0	$	2,007,405

Exercisable December 31, 2018		1,269,295		$	1.80		7.1	$	1,628,480

The following table presents information related to stock options as of December 31, 2018:

Options Outstanding			Options Exercisable
			Weighted
	Outstanding		Average		Exercisable
Exercise	Number of		Remaining Life		Number of
Price	Options		In Years		Options
$ 1.24		760,001		6.2		760,001
$ 1.95		868,782		8.5		447,754
$ 4.00		2,000		-		-
$ 5.10		6,000		-		-
$ 5.19		16,500		-		-
$ 5.25		26,668		7.8		14,584
$ 6.20		311,499		-		-
$ 6.30		60,000		9.5		8,333
$ 8.72		169,418		9.3		38,623
		2,220,868		7.1		1,269,295

Stock Warrants

On September 27, 2017, the Company issued a warrant to purchase 61,875 shares of common stock at an exercise price of $6.98 per share to an investor for cash consideration of $431,574, which was included within additional paid-in capital on the balance sheet as of December 31, 2017. The warrant is exercisable any time through September 27, 2027. The warrant was sold to an investor for the amount of the investment in excess of what was permitted to be purchased of Series B Convertible Preferred Stock.

During the year ended December 31, 2018, warrants to purchase an aggregate of 61,875 shares of common stock with an exercise price of $0.04 per share were exercised on a cashless basis, which resulted in the issued of an aggregate of 61,385 shares of common stock.

A summary of the warrant activity during the year ended December 31, 2018 is presented below:

							Weighted
				Weighted			Average
				Average			Remaining		Aggregate
	Number of			Exercise			Life		Intrinsic
	Warrants			Price			In Years		Value
Outstanding January 1, 2018		61,875			6.98
Granted		-			-
Exercised		(61,875	)		(6.98	)
Forfeited		-			-
Outstanding December 31, 2018		-		$	-			-	$	-

Exercisable December 31, 2018		-		$	-			-	$	-

Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 11 – Subsequent Events

Stock Options

On January 2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888.

On February 6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.

On February 13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr. Ianchulev on July 24, 2018 in connection with his employment.

Employment Agreements

Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President, Research and Development and Manufacturing, and Michael Rowe, its Vice President, Marketing.

Each of the employment agreements provides that if the executive’s employment is terminated by the Company without “Cause” or the executive suffers an “Involuntarily Termination” (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.

Each of the employment agreements also provides that if within 12 months following any “Corporate Transaction” (as defined in the employment agreements) of the Company, if the executive’s employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Liquidity and Financial Condition [Policy Text Block]

Liquidity and Financial Condition

On January 29, 2018, the Company raised aggregate net proceeds of approximately $24.5 million in its initial public offering (“IPO”).

On December 21, 2018, the Company raised aggregate net proceeds of approximately $2.8 million in its follow-on public offering.

See Note 9 – Stockholders’ Equity – Public Offerings for additional details.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

See Note 2 - Summary of Significant Accounting Policies — Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment, Net

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

Deferred Charges, Policy [Policy Text Block]

Deferred Offering Costs

Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]

Preferred Stock

Derivatives, Policy [Policy Text Block]

Convertible Instruments

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

The Company’s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of

operations. The Company did not recognize any such penalties or interest during 2017 and 2018.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

Valuation of Privately-Held-Company Equity Securities Issued as Compensation

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Common Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2018		2017
Options		2,220,868		1,684,416
Restricted Stock Units		20,165		-
Series A Convertible Preferred Stock		-		2,932,431
Series A-2 Convertible Preferred Stock		-		788,827
Series B Convertible Preferred Stock		-		918,983
Warrant		-		61,875
Total potentially dilutive shares		2,241,033		6,386,532

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

Company does not expect the adoption of ASU 2016-15 will have a material impact on its financial position, results of operations, and cash flows.

Recently Adopted Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2018		2017
Options		2,220,868		1,684,416
Restricted Stock Units		20,165		-
Series A Convertible Preferred Stock		-		2,932,431
Series A-2 Convertible Preferred Stock		-		788,827
Series B Convertible Preferred Stock		-		918,983
Warrant		-		61,875
Total potentially dilutive shares		2,241,033		6,386,532

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2018

Prepaid Expense and Other Assets [Abstract]

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

As of December 31, 2018 and 2017, prepaid expenses and other current assets consisted of the following:

	December 31,
	2018		2017
Prepaid rent and security deposit	$	75,729	$	-
Prepaid insurance expenses		39,465		384
Prepaid patent expenses		10,562		7,833
Prepaid conference expenses		7,000		-
Prepaid research and development expenses		-		28,932
Total prepaid expenses and other current assets	$	132,756	$	37,149

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

As of December 31, 2018 and 2017, property and equipment consisted of the following:

	December 31,
	2018			2017
Equipment	$	62,886		$	34,979
Leasehold improvements		40,000			40,000
		102,886			74,979
Less: accumulated depreciation and amortization		(66,148	)		(47,019	)
Property and equipment, net	$	36,738		$	27,960

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

As of December 31, 2018 and 2017, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2018		2017
Accrued research and development expenses		375,204		120,455
Accrued legal expenses		168,650		-
Accrued professional services		111,728		41,831
Other		12,165		1,134
Credit card payable		9,466		9,843
Accrued offering costs		-		133,000
Total accrued expenses and other current liabilities	$	677,213	$	306,263

Accrued Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Accrued compensation [Table Text Block]

As of December 31, 2018 and 2017, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2018		2017
Accrued bonus expenses	$	694,490	$	-
Accrued payroll expenses		217,614		-
Total accrued expenses and other current liabilities	$	912,104	$	-

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The income tax (provision) benefit consists of the following:

	For The Year Ended
	December 31,
	2018			2017
Federal:
Current	$	-		$	-
Deferred		3,516,722			235,473
State and local:
Current		-			-
Deferred		47,238			80,301
		3,563,960			315,774
Change in valuation allowance		(3,563,960	)		(315,774	)
Income tax (provision) benefit	$	-		$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	For The Years Ended
	December 31,
	2018			2017
Tax benefit at federal statutory rate		21.0	%		34.0	%
State income taxes, net of federal benefit		0.3	%		4.0	%
Permanent differences		(0.8	)%		0.0	%
Research and development credits		2.8	%		6.3	%
Prior period adjustments and other		(2.6	)%		(8.1	)%
Effect of tax rate changes		0.0	%		(30.0	)%
Change in valuation allowance		(20.7	)%		(6.2	)%
Effective income tax rate		0.0	%		0.0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:

	December 31,
	2018			2017
Deferred Tax Assets:
Net operating loss carryforwards	$	5,453,854		$	2,588,641
Stock-based compensation		616,207			347,977
Research & development tax credits		1,008,443			526,134
Property & equipment		2,486			-
Intangible assets		310,230			364,508
Gross deferred tax assets		7,391,220			3,827,260
Valuation allowance		(7,391,220	)		(3,827,260	)
Deferred tax asset, net of valuation allowance	$	-		$	-

Changes in valuation allowance	$	(3,563,960	)	$	(315,774	)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Future minimum payments under this operating lease agreement are as follows as:

For the Year Ending December 31,	Minimum Lease Payments
2019	$	238,300
2020		244,853
2021		251,586
2022		258,505
2023		198,157
	$	1,191,401

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Year Ended
	December 31,
	2018			2017
Expected term (years)		5.50 - 10.00			5.32 - 10.00
Risk free interest rate		2.69 - 3.24	%		1.95 - 2.39	%
Expected volatility		140 -141	%		130	%
Expected dividends		0.00	%		0.00	%

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the option activity during the year ended December 31, 2018 is presented below:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value
Outstanding January 1, 2018		1,684,416		$	1.68
Granted		571,667			6.94
Exercised		(28,965	)		1.95
Forfeited		(6,250	)		8.72
Outstanding December 31, 2018		2,220,868		$	3.01		8.0	$	2,007,405

Exercisable December 31, 2018		1,269,295		$	1.80		7.1	$	1,628,480

Schedule Of Share Based Compensation Shares Outstanding UnderStock Option Plans By Exercise Price Range [Table Text Block]

The following table presents information related to stock options as of December 31, 2018:

Options Outstanding			Options Exercisable
			Weighted
	Outstanding		Average		Exercisable
Exercise	Number of		Remaining Life		Number of
Price	Options		In Years		Options
$ 1.24		760,001		6.2		760,001
$ 1.95		868,782		8.5		447,754
$ 4.00		2,000		-		-
$ 5.10		6,000		-		-
$ 5.19		16,500		-		-
$ 5.25		26,668		7.8		14,584
$ 6.20		311,499		-		-
$ 6.30		60,000		9.5		8,333
$ 8.72		169,418		9.3		38,623
		2,220,868		7.1		1,269,295

Schedule Of Warrants Outstanding [Table Text Block]

A summary of the warrant activity during the year ended December 31, 2018 is presented below:

							Weighted
				Weighted			Average
				Average			Remaining		Aggregate
	Number of			Exercise			Life		Intrinsic
	Warrants			Price			In Years		Value
Outstanding January 1, 2018		61,875			6.98
Granted		-			-
Exercised		(61,875	)		(6.98	)
Forfeited		-			-
Outstanding December 31, 2018		-		$	-			-	$	-

Exercisable December 31, 2018		-		$	-			-	$	-

Business Organization and Nature of Operations (Details Textual)	12 Months Ended
	Dec. 31, 2018
Entity Incorporation, State Country Name	Florida
Entity Incorporation, Date of Incorporation	Mar. 12, 2014
Percentage reduction in preservative	75.00%

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,241,033	6,386,532
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,165	0
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	61,875
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,220,868	1,684,416
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,932,431
Series A-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	788,827
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	918,983

Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 21, 2018	Jan. 29, 2018	Dec. 31, 2018	Dec. 31, 2017
Proceeds from Issuance Initial Public Offering	$ 2,800,000	$ 24,500,000
Cash, Uninsured Amount			$ 19,478,200	$ 4,999,511
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Minimum [Member]
Property, Plant and Equipment, Useful Life			2 years

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expense and Other Assets [Abstract]
Prepaid rent and security deposit	$ 75,729	$ 0
Prepaid insurance expenses	39,465	384
Prepaid patent expenses	10,562	7,833
Prepaid conference Expenses	7,000	0
Prepaid research and development expenses	0	28,932
Total prepaid expenses and other current assets	$ 132,756	$ 37,149

Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross	$ 102,886	$ 74,979
Less: accumulated depreciation and amortization	(66,148)	(47,019)
Property and equipment, net	36,738	27,960
Equipment [Member]
Property, Plant and Equipment, Gross	62,886	34,979
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	$ 40,000	$ 40,000

Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
Property and Equipment, Net (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Depletion and Amortization	$ 19,129	$ 25,466
Research and Development Expense	11,119,096	3,816,732
General and Administrative Expense	6,137,347	1,315,635
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization	19,129	25,466
Research and Development Expense	17,966	25,466
General and Administrative Expense	$ 1,163	$ 0

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued research and development expenses	$ 375,204	$ 120,455
Accrued legal expenses	168,650	0
Accrued professional services	111,728	41,831
Other	12,165	1,134
Credit card payable	9,466	9,843
Accrued offering costs	0	133,000
Total accrued expenses and other current liabilities	$ 677,213	$ 306,263

Accrued Compensation (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued bonus expenses	$ 694,490	$ 0
Accrued payroll expenses	217,614	0
Total accrued expenses and other current liabilities	$ 912,104	$ 0

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Federal:
Current	$ 0	$ 0
Deferred	3,516,722	235,473
State and local:
Current	0	0
Deferred	47,238	80,301
Income Tax Expense Benefit Before Adjustments For Change In Valuation Allowance	3,563,960	315,774
Change in valuation allowance	(3,563,960)	(315,774)
Income tax (provision) benefit	$ 0	$ 0

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2018	Dec. 31, 2017
Tax benefit at federal statutory rate	21.00%	34.00%
State income taxes, net of federal benefit	0.30%	4.00%
Permanent differences	(0.80%)	0.00%
Research and development credits	2.80%	6.30%
Prior period adjustments and other	(2.60%)	(8.10%)
Effect of tax rate changes	0.00%	(30.00%)
Change in valuation allowance	(20.70%)	(6.20%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Details 2) - USD ($)	12 Months Ended
Income Taxes (Details 2) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred Tax Assets:
Net operating loss carryforwards	$ 5,453,854	$ 2,588,641
Stock-based compensation	616,207	347,977
Research & development tax credits	1,008,443	526,134
Property & equipment	2,486	0
Intangible assets	310,230	364,508
Gross deferred tax assets	7,391,220	3,827,260
Valuation allowance	(7,391,220)	(3,827,260)
Deferred tax assets, net of valuation allowance	0	0
Changes in valuation allowance	$ (3,563,960)	$ (315,774)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards	$ 25,600,000
Operating Loss Carry forwards Expiration Term	2034 to 2038
Tax Credit Carryforward, Limitations on Use	In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforwards could become subject to annual limitations if there are greater than 50% ownership changes.
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 1,500,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		$ 1,500,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 14,800,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$ 10,800,000
Maximum [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 500,000

Commitments and Contingencies (Details)	Dec. 31, 2018 USD ($)
2019	$ 238,300
2020	244,853
2021	251,586
2022	258,505
2023	198,157
Minimum Lease Payments	$ 1,191,401

Commitments and Contingencies (Details Textual)		1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Textual)	Aug. 08, 2018 USD ($) ft²	Oct. 29, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Loss Contingency, Damages Sought, Value		$ 600,000	$ 1,100,000
Malpractice Loss Contingency, Insurance Recoveries		10,000,000
Net Rentable Area \| ft²	3,800
Operating Leases, Rent Expense, Net	$ 1,236,000
Security Deposit	$ 118,000		$ 117,800	$ 0
Lease Expiration Date	Sep. 30, 2023
Loss Contingency Accrual, Payments		150,000
Malpractice Loss Contingency, Claims Incurred in Period		$ 450,000
Minimum [Member]
Operating Leases Monthly Rental Payments	$ 19,633
Maximum [Member]
Operating Leases Monthly Rental Payments	$ 22,486

Related Party Transactions (Details Textual)			1 Months Ended				12 Months Ended
Related Party Transactions (Details Textual)	Jul. 07, 2017 $ / shares shares	Jul. 06, 2017 USD ($)	Apr. 16, 2018 $ / shares shares	Jan. 31, 2018 USD ($)	Sep. 15, 2016 USD ($) ft²	Jul. 31, 2016 USD ($)	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2015	Sep. 15, 2018 USD ($)	Aug. 08, 2018 USD ($) ft²
Operating Leases, Rent Expense							$ 32,000	$ 36,000
Net Rentable Area \| ft²											3,800
Security Deposit							$ 117,800	$ 0			$ 118,000
Minority Interest Ownership Percentage In Company							5.00%
Payments for Rent				$ 4,000		$ 3,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 1.95		$ 8.72				$ 6.39	$ 1.77
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	36 months		36 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 173,900
Officers' Compensation							$ 165,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	897,747		175,668
Vice President of Research and Development [Member]
Cost Of Services Engineering Services							863,555	$ 1,155,000
Net Rentable Area \| ft²					953
Lease, Monthly Base Rent					$ 3,895
Operating Lease, Expense							47,270	45,678
Security Deposit					$ 3,895					$ 4,012
Officers Compensation Per Month		$ 9,167
Officers Compensation Per Hour		175
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 1.95
Officers' Compensation							182,275	27,500
Leasehold Improvements, Gross							40,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	100,264
Senju Pharmaceutical Co [Member]
Royalty Percentage									(5.00%)
Research and Development Expense [Member] \| Vice President of Research and Development [Member]
Due to Related Parties							100,667	94,998
Related to expenses incurred							0	9,906
Cura Partners [Member] \| Consulting Agreement [Member]
Consulting agreement payment, Per month		9,567
Consulting agreement payment, Per hour		$ 250
Cura Partners [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party							162,929	85,835
Private Medical Equity, Inc. [Member]
Consulting Fee							$ 33,200
Private Medical Equity, Inc. [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								329,400
Private Medical Equity, Inc. [Member] \| Research and Development Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								176,344
Private Medical Equity, Inc. [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								$ 152,656

Stockholders' Equity (Details)	12 Months Ended
Stockholders' Equity (Details)	Dec. 31, 2018	Dec. 31, 2017
Risk free interest rate, Minimum	2.69%	1.95%
Risk free interest rate, Maximum	3.24%	2.39%
Expected volatility		130.00%
Expected dividends	0.00%	0.00%
Maximum [Member]
Expected term (years)	10 years	10 years
Expected volatility	141.00%
Minimum [Member]
Expected term (years)	5 years 6 months	5 years 3 months 25 days
Expected volatility	140.00%

Stockholders' Equity (Details 1) - USD ($)		1 Months Ended	12 Months Ended
Stockholders' Equity (Details 1) - USD ($)	Jul. 07, 2017	Apr. 16, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of Options Granted \| Shares	897,747	175,668
Weighted Average Exercise Price, Granted \| $ / Shares	$ 1.95	$ 8.72	$ 6.39	$ 1.77
Equity Option [Member]
Number of Options Outstanding \| Shares			1,684,416
Number of Options Granted \| Shares			571,667
Number of Options Exercised \| Shares			(28,965)
Number of Options Forfeited \| Shares			(6,250)
Number of Options Outstanding \| Shares			2,220,868	1,684,416
Number of Options Exercisable \| Shares			1,269,295
Weighted Average Exercise Price, Outstanding \| $ / Shares			$ 1.68
Weighted Average Exercise Price, Granted \| $ / Shares			6.94
Weighted Average Exercise Price, Exercised			1.95
Weighted Average Exercise Price, Forfeited \| $ / Shares			8.72
Weighted Average Exercise Price, Outstanding \| $ / Shares			3.01	$ 1.68
Weighted Average Exercise Price, Exercisable \| $ / Shares			$ 1.80
Weighted Average Remaining Life In Years, Outstanding			8 years
Weighted Average Remaining Life In Years, Exercisable			7 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding \| $			$ 2,007,405
Aggregate Intrinsic Value, Exercisable			$ 1,628,480

Stockholders' Equity (Details 2)	12 Months Ended
Stockholders' Equity (Details 2)	Dec. 31, 2018 $ / shares shares
Options Outstanding, Outstanding Number of Options	2,220,868
Options Exercisable, Weighted Average Remaining Life In Years	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	1,269,295
Exercise Price 1.24 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.24
Options Outstanding, Outstanding Number of Options	760,001
Options Exercisable, Weighted Average Remaining Life In Years	6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	760,001
Exercise Price 1.95 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.95
Options Outstanding, Outstanding Number of Options	868,782
Options Exercisable, Weighted Average Remaining Life In Years	8 years 6 months
Options Exercisable, Exercisable Number of Options	447,754
Exercise Price 4.00 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 4.00
Options Outstanding, Outstanding Number of Options	2,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.10 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.10
Options Outstanding, Outstanding Number of Options	6,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.19 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.19
Options Outstanding, Outstanding Number of Options	16,500
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.25 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.25
Options Outstanding, Outstanding Number of Options	26,668
Options Exercisable, Weighted Average Remaining Life In Years	7 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	14,584
Exercise Price 6.20 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.20
Options Outstanding, Outstanding Number of Options	311,499
Options Exercisable, Exercisable Number of Options	0
Exercise Price 6.30 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.30
Options Outstanding, Outstanding Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	8,333
Exercise Price 8.72 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 8.72
Options Outstanding, Outstanding Number of Options	169,418
Options Exercisable, Weighted Average Remaining Life In Years	9 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	38,623

Stockholders' Equity (Details 3) - Warrant [Member]	12 Months Ended
Stockholders' Equity (Details 3) - Warrant [Member]	Dec. 31, 2018 USD ($) $ / shares shares
Number of Warrants, Outstanding \| shares \| shares	61,875
Number of Warrants, Granted \| shares \| shares	0
Number of Warrants, Exercised \| shares \| shares	(61,875)
Number of Warrants, Forfeited \| shares \| shares	0
Number of Warrants, Outstanding \| shares \| shares	0
Number of Warrants, Exercisable \| shares \| shares	0
Weighted Average Exercise Price, Outstanding \| $ / shares \| $ / shares	$ 6.98
Weighted Average Exercise Price, Granted \| $ / shares \| $ / shares	0
Weighted Average Exercise Price,Exercised \| $ / shares \| $ / shares	(6.98)
Weighted Average Exercise Price, Forfeited \| $ / shares \| $ / shares	0
Weighted Average Exercise Price, Outstanding \| $ / shares \| $ / shares	0
Weighted Average Exercise Price, Exercisable \| $ / shares \| $ / shares	$ 0
Weighted Average Remaining Life In Years, Outstanding	0 years
Weighted Average Remaining Life In Years, Exercisable	0 years
Aggregate Intrinsic Value, Outstanding \| $ \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $ \| $	$ 0

Stockholders' Equity (Details Textual) - USD ($)

1 Months Ended

12 Months Ended

Jan. 08, 2018

Jul. 07, 2017

Jul. 06, 2017

Dec. 21, 2018

Jul. 24, 2018

Apr. 16, 2018

Jan. 29, 2018

Sep. 27, 2017

Dec. 31, 2018

Dec. 31, 2017

Mar. 06, 2018

Jan. 05, 2018

Common Stock, Shares Authorized

90,000,000

Preferred Stock, Shares Authorized

6,000,000

Stock Issued During Period, Shares, New Issues

2,730,000

Shares Issued, Price Per Share

$ 10.00

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 3,730,911

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

2 years 2 months 12 days

Net Proceeds from Issuance of Common Stock

$ 24,500,000

Payment of Financing and Stock Issuance Costs

$ 2,800,000

Convertible Preferred Stock, Shares Issued upon Conversion

4,702,116

Share-based Compensation Arrangement by Share-based Payment Award, Description

vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months

Gross Proceeds Of Stock Value Issued During Period

$ 27,300,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value

$ 1,412,700

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

36 months

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

897,747

175,668

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.95

$ 8.72

$ 6.39

$ 1.77

Share-based Compensation

$ 1,615,470

$ 412,312

Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value

$ 1,585,700

$ 2,237,800

Stockholders' Equity, Reverse Stock Split

1-for-3.75

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 6.98

$ 0.04

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

61,875

Common Stock, Par or Stated Value Per Share

$ 0.0001

Preferred Stock, Par or Stated Value Per Share

$ 0.0001

Preferred Stock Prorata Allotment Pecentage

75.00%

Payments of Stock Issuance Costs

$ 0

$ 41,958

Proceeds from Issuance of Warrants

$ 431,574

431,574

Proceeds from Issuance of Common Stock

^[1]

$ 25,089,000

$ 0

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

20,165

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 125,000

Warrant [Member]

Stock Issued During Period, Shares, New Issues

61,385

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

Common Stock [Member]

Stock Issued During Period, Shares, New Issues

^[2]

Shares Issued, Price Per Share

$ 2.45

Payment of Financing and Stock Issuance Costs

$ 600,000

Stock Issued During Period Shares New Issues Two

1,380,000

^[3]

Proceeds from Issuance of Common Stock

$ 3,400,000

Proceeds Of Stock Issued During Period Gross

$ 2,800,000

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

12 months

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

100,002

313,674

Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

36 months

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

797,745

60,000

Share-based Compensation Award, Tranche Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

22,325

Non-Employee Grants [Member]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 396,924

Maximum [Member]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6.30

Minimum [Member]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 5.10

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

12,833

2014 Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,866,667

2014 Equity Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,733,333

Omnibus Stock Incentive Plan 2018 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

333,836

Employees Consultants and Directors Under the 2018 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

395,999

Series A Convertible Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues

^[2]

Preferred Stock Prorata Allotment Pecentage

75.00%

Preferred Stock Shares Not Participating In Financings

299,863

Preferred Stock Designated Shares

20,000,000

Stock Issued During Period Shares New Issues Two

^[3]

Series And Series A2 Convertible Preferred Stock [Member]

Convertible Preferred Stock, Terms of Conversion

Series B Convertible Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues

^[2]

918,983

Shares Issued, Price Per Share

$ 6.98

Convertible Preferred Stock, Terms of Conversion

Preferred Stock Shares Not Participating In Financings

299,863

Preferred Stock Designated Shares

10,000,000

Gross Proceeds From Issuance Of Convertible Preferred Stock

$ 6,409,651

Payments of Stock Issuance Costs

41,958

Net Proceeds From Issuance Of Preferred Stock And Preference Stock

$ 6,367,693

Stock Issued During Period Shares New Issues Two

^[3]

[1]	Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.
[2]	Includes gross proceeds of $6,409,651, less issuance costs of $41,958.
[3]	Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.